OncoKB New Data Release - September 25, 2024
Contact OncoKB
Data Release v4.21
September 25, 2024
What's New
Updated Therapeutic Implications:
New alteration(s) with a tumor type-specific level of evidence
Level 3A: MET H1094Y and F1200I in non-small cell lung cancer based on clinical response to elzovantinib in patients with MET-mutated non-small cell lung cancer, and accompanying preclinical data (PMID: 38564707)
Level 4: MET N1100S, V1092I, H1106D, R1170Q and M1250T in non-small cell lung cancer based on clinical response to elzovantinib in patients with MET tyrosine kinase domain-mutated non-small cell lung cancer, and accompanying preclinical data demonstrating sensitivity to elzovantinib, capamtinib and tepotinib (PMID: 38564707)
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Amivantamab + Lazertinib to the Level 1 annotation of EGFR exon 19 in-frame deletions and L858R in non-small cell lung cancer based on FDA approval of amivantamab + lazertinib in patients with non-small cell lung cancer with EGFR L858R or exon 19 in-frame deletions (PMID: 38924756)
Amivantamab + Lazertinib was previously Level 3A in this indication
Sensitivity-associated evidence currently in OncoKB™ for EGFR exon 19 in-frame deletions and L858R (Level 1 in non-small cell lung cancer; Afatinib, Dacomitinib, Erlotinib, Erlotinib + Ramucirumab, Gefitinib, Osimertinib, Osimertinib + Chemotherapy)
Gene Curation:
Addition of 8 new genes:
ABCB1 ACVR2A ADGRA2 BCL2L2 ELL2 FANCI USP1 XPA
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
